Table 1.

Sustained virological response (SVR) in hepatitis C virus according to genotypes

References	G	Number of patients	Naïve	Formula of therapy	Duration of treatment (weeks)	SVR (%)
McHutchison et al. [99]	1	3,070	Yes	PegIFN-α-2b 1.5 μg/kg per week + RBV 800–1,400 mg/day	48	39.8
				PegIFN-α-2b 1.0 μg/kg per week + RBV 800–1,400 mg/day	48	38.0
				PegIFN-α-2a 180 μg/week + RBV 1,000–1,200 mg/day	48	40.9
Yamada et al. [100]	1	192	Yes	PegIFN-α-2a 180 μg/week + RBV 600–1,000 mg/day	48	59.4
				PegIFN-α-2a 180 μg/week + placebo	48	24.0
Liu et al. [101]	1	110		PegIFN-α-2a 180 μg/week + RBV 1,000–1,200 mg/day	48	77.3
	2	50		PegIFN-α-2a 180 μg/week + RBV 800 mg/day	24	84.0
Liu et al. [17]	1	308		PegIFN-α-2a 180 μg/week + RBV 1,000–1,200 mg/day	48	76
				PegIFN-α-2a 180 μg/week + RBV 1,000–1,200 mg/day	24	56
Shiffman et al. [102]	2 or 3	1,469	Yes	PegIFN-α-2a 180 μg/week + RBV 800 mg/day	16	62
					24	70
Mangia et al. [103]	2	213		PegIFN-α-2b 1.0 μg/kg per week + RBV 1,000 or 1,200 mg/day	12 or 24	80
	3	70				60
El-Zayadi et al. [104]	4	110	Yes	PegIFN-α-2b 1.0 μg/kg per week + RBV 1,000–1,200 mg/day	48	55.0
				PegIFN-α-2b 1.0 μg/kg per week + RBV 1,000–1,200 mg/day	24	48.6
Roulot et al. [105]	4	242	Yes	PegIFN-α-2b 1.5 μg/kg per week + RBV 1,000–1,200 mg/day	48	32.4–54.9
Bonny et al. [106]	5	27	Yes	IFN-α-2b 3MU × 3/week + RBV 1,000–1,200 mg/day	48	60
Nguyen et al. [107]	6	34	Yes	PegIFN + RBV	48	74
	6	27	Yes	PegIFN + RBV	24	63
	1	70	Yes	PegIFN + RBV	48	49
	2 or 3	36	Yes	PegIFN + RBV	24	75
Fung et al. [108]	1	21	Yes	PegIFN + RBV	48	52
	6	21	Yes	PegIFN + RBV	48	86

G genotype, Naïve treatment-naïve